Exelixis, Inc. (EXEL)
| Market Cap | 6.25B |
| Revenue (ttm) | 1.52B |
| Net Income (ttm) | 298.04M |
| Shares Out | 320.74M |
| EPS (ttm) | 0.72 |
| PE Ratio | 27.07 |
| Forward PE | 20.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,493,826 |
| Open | 20.46 |
| Previous Close | 20.69 |
| Day's Range | 19.45 - 20.73 |
| 52-Week Range | 15.50 - 24.75 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 27.71 (+42.2%) |
| Earnings Date | May 10, 2022 |
About EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, inclu...
Financial Performance
In 2021, Exelixis's revenue was $1.43 billion, an increase of 45.31% compared to the previous year's $987.54 million. Earnings were $231.06 million, an increase of 106.71%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is 27.71, which is an increase of 42.18% from the latest price.
News
Can This Cancer Stock Maintain Its Momentum?
This biotech stock has been on fire since the beginning of the year.
Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make
With thrilling long-term prospects, these three are excellent buys.
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates
Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objective...
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
Why Exelixis (EXEL) Might Surprise This Earnings Season
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences in ...
3 Growth Stocks to Buy With $1,000 Right Now
A small investment can go a long way.
Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previou...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy ...
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p...
Stock Market Bounces, But Be Wary; Watch Exelixis, World Wrestling Entertainment, Marriott
Stock Market Bounces, But Be Wary; Watch Exelixis, World Wrestling Entertainment, Marriott Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, in...
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgk...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that in...
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Charles Cohen, Ph.D. has notified the company of his decision to retire from the Exelixis Board of Directors. Dr. Coh...
Nasdaq Bear Market: 3 of the Safest Stocks to Buy on the Dip
A tumbling market is the perfect time to invest in these pillars of stability.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 No-Brainer Stocks to Buy With $1,000 During the Market Sell-Off
A tumbling market is the perfect opportunity to buy into these highly profitable and attractively priced stocks.
2 Stocks Defying the Market Sell-Off Right Now
Are these two companies solid long-term bets?
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Tre...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the sci...
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Announces Final Results From HCC Study
Exelixis (EXEL) does not intend to submit a supplemental new drug application to the FDA for Cabometyx in patients with previously untreated advanced hepatocellular carcinoma.
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with a...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial,...